News

New brain tumor gene identified for meningiomas
Aug 08, 2011
The causes of brain tumors have been hard to discern in most cases. But an international collaboration of researchers have discovered a genetic variation--a gene variant that is close to MLLT10 on chromosome 10--that increases the risk of meningiomas.
Scientists map genes for oligodendroglioma
Aug 05, 2011
Johns Hopkins Kimmel Cancer Center scientists have completed a comprehensive map of genetic mutations occurring in the second-most common form of brain cancer, oligodendroglioma. The findings, reported in the August 4 issue of Science, also appear to reveal the biological cause of the tumors.
Stem cells restore cognitive abilities impaired by brain cancer treatment
Jul 13, 2011
Human neural stem cells are capable of helping people regain learning and memory abilities lost due to radiation treatment for brain tumors, a UC Irvine study suggests.
Indirubin—component of Chinese herbal remedy—might block brain tumor spread
Jul 12, 2011
Ohio State University researchers have discovered that the compound indirubin both blocks the migration of glioblastoma cells, preventing their spread to other areas of the brain, and the migration of endothelial cells, preventing them from forming the new blood vessels that the tumor needs to grow.
Exercise associated with longer survival after brain cancer diagnosis
Jun 21, 2011
Brain cancer patients who are able to exercise live significantly longer than sedentary patients, scientists at the Duke Cancer Institute report.
Vaccine study supports immune targeting of brain tumors
Jun 16, 2011
An experimental vaccine developed by researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute targets overactive antigens in highly aggressive brain tumors and improves length of survival in newly diagnosed patients, according to new data that was presented in a poster session at the 47th Annual Meeting of the American Society of Clinical Oncology.
Study finds vaccine extends recurrent gliobastoma survival rates by 2 to 3 times
Jun 03, 2011
In data presented at The American Society of Clinical Oncology Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma has a favorable safety profile and extends survival by 2 to 3 times more than the current median survival rate.
Iron key to brain tumor drug delivery
Jun 02, 2011
Brain cancer therapy may be more effective if the expression of an iron-storing protein is decreased to enhance the action of therapeutic drugs on brain cancer cells, according to Penn State College of Medicine researchers.
Minimizing side effects from chemoradiation could help brain cancer patients live longer
Apr 19, 2011
Minimizing neurologic side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests.
FDA approves new medical device for form of brain cancer
Apr 15, 2011
The US Food and Drug Administration recently approved the NovoTTF-100A System, a new device to treat adults with glioblastoma multiforme that recurs or progresses after receiving chemotherapy and radiation therapy.
Scientists find potential benefit of hypericin for recurrent brain tumors
Apr 08, 2011
Researchers have found that a synthetic version of hypericin, a compound naturally found in St John's wort, may be a promising treatment for patients with recurrent malignant brain tumors. Their findings were published online on March 31, 2011 in the journal Cancer.
Epileptic seizures linked to significant risk of subsequent brain tumor
Apr 06, 2011
Epileptic seizures can precede the development of a subsequent brain tumor by many years, suggests research published online in the Journal of Neurology, Neurosurgery and Psychiatry.
Research targets way to stop brain tumor cell invasion
Mar 29, 2011
A study finds that the drug Icatibant, which is already in use in Europe, and its ability to block B2R receptors may prove to be a very promising target for further investigation for the treatment of malignant gliomas.